晚期胆囊癌患者应用甲磺酸阿帕替尼治疗的效果及安全性研究

Efficacy and Safety of Apatinib Mesylate in Patients with Advanced Gallbladder Cancer

目的:探讨晚期胆囊癌患者应用甲磺酸阿帕替尼治疗的效果及安全性。方法:选取笔者所在医院接受治疗的60例晚期胆囊癌患者,选取时间为2017年1月-2018年1月。将其按照盲选方法分为两组,每组30例。对照组给予静脉滴注吉西他滨治疗,研究组则给予口服甲磺酸阿帕替尼片治疗。比较两组近期疗效、不良反应及血清肿瘤标志物水平,随访1年观察两组生存期。结果:两组客观缓解率(RR)和疾病控制率(DCR)比较,差异均无统计学意义(P>0.05)。研究组血压升高、蛋白尿及手足综合征等不良反应发生率均明显低于对照组,差异有统计学意义(P<0.05)。研究组治疗后血清肿瘤标志物水平改善情况明显优于对照组,差异有统计学意义(P<0.05)。研究组平均生存时间明显长于对照组,差异有统计学意义(P<0.01)。结论:晚期胆囊癌患者应用甲磺酸阿帕替尼治疗的近期疗效与吉西他滨相当,且能够减少不良反应,降低血清肿瘤标志物水平,同时可有效延长患者的生存期,远期疗效佳,应用安全性高。

Objective:To investigate the efficacy and safety of Apatinib Mesylate in patients with advanced gallbladder cancer.Method:Sixty patients with advanced gallbladder cancer who were treated in our hospital were selected.The selected time was from January 2017 to January 2018.They were divided into two groups according to the blind selection method,30 cases in each group.The control group was treated with intravenous Gemcitabine,and the study group was treated with oral Apatinib Mesylate Tablets.The short-term efficacy,adverse reactions,and serum tumor markers of the two groups were compared,and the survival time of the two groups was observed after 1 year of follow-up.Result:There were no significant differences in the objective remission rate(RR)and disease control rate(DCR)between the two groups(P>0.05).The incidence of adverse reactions such as elevated blood pressure,proteinuria and hand-foot syndrome in the study group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).The improvement of serum tumor marker levels in the study group was significantly better than that in the control group,the difference was statistically significant(P<0.05).The average survival time of the study group was significantly longer than that of the control group,and the difference was statistically significant(P<0.01).Conclusion:The short-term efficacy of Apatinib Mesylate in patients with advanced gallbladder cancer is comparable to that of Gemcitabine,and it can reduce the adverse reactions,reduce the level of serum tumor markers,and effectively prolong the survival period of patients,with good long-term efficacy and high application safety.